NEW YORK, June 16, 2017 /PRNewswire/ --
DailyStockTracker.com today reviews Illumina Inc. (NASDAQ: ILMN), NavideaBiopharmaceuticals Inc (NYSE MKT: NAVB), Grifols S.A. (NASDAQ: GRFS), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). According to an article on Hargreaves Lansdown, the Biotechnology sector could continue to face periods of volatility in the short-term
Register now and get full and free access to these DailyStockTracker.com research reports at:
On Thursday, shares in San Diego, California headquartered Illumina Inc. recorded a trading volume of 781,481 shares. The stock ended at $172.04, declining 0.32% from the last trading session. The Company's shares have gained 7.89% over the previous three months and 34.36% on an YTD basis. The stock is trading above its 200-day moving average by 7.49%. Furthermore, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 40.96.
On May 22nd, 2017, Illumina announced that Mark Van Oene has been named Chief Commercial Officer. Van Oene was previously the Company's Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. As Chief Commercial Officer, Van Oene will be responsible for worldwide sales, services, and marketing at the Company. He will report to President and CEO, Francis deSouza. Access our complete research report on ILMN for free at:
Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc's stock finished yesterday's session 0.83% lower at $0.52 with a total trading volume of 271,781 shares. The Company's shares have gained 13.87% in the last one month. The stock is trading above its 50-day moving average by 7.43%. Furthermore, shares of Navidea Biopharma, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 57.64.
On June 12th, 2017, Navidea Biopharma announced that its European commercial partner, SpePharm AG, an affiliate of Norgine, B.V., launched LYMPHOSEEK® (technetium TC 99m tilmanocept), originally developed by the Company in Denmark, the Netherlands, and the UK. LYMPHOSEEK® is specifically designed to target, bind to, and be retained in sentinel lymph nodes, the first lymph node, or group of nodes, to which cancer cells are most likely to spread from a primary tumor. The complimentary research report on NAVB can be downloaded at:
At the close of trading on Thursday, shares in Barcelona, Spain headquartered Grifols S.A. saw a slight decline of 0.52%, ending the day at $21.06. The stock recorded a trading volume of 382,098 shares. The Company's shares have advanced 21.31% in the previous three months and 31.05% since the start of this year. The stock is trading 1.24% and 20.83% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 51.15.
On June 12th, 2017, Grifols and Beckman Coulter Inc., a leading provider of innovative, efficient and reliable diagnostics solutions, have entered into an exclusive, long-term agreement for the global distribution of the former's hemostasis instruments, reagents, and consumables. The agreement leverages Grifols' strength in manufacturing reliable instruments and reagents with that of Beckman Coulter's commercial strength. Register for free on DailyStockTracker.com and get access to the latest report on GRFS at:
New York headquartered Intercept Pharmaceuticals Inc.'s shares ended the day 2.99% lower at $118.12 with a total trading volume of 282,074 shares. The stock has gained 8.72% on an YTD basis. The Company's shares are trading 3.84% above their 50-day moving average. Additionally, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have an RSI of 54.00.
On May 19th, 2017, Intercept Pharma announced that it has received a 2017 Industry Innovation Award from the National Organization for Rare Disorders for the development of Ocaliva (obeticholic acid). This award recognizes the Company's commitment to the rare disease community and the impact Ocaliva has made in the lives of patients with primary biliary cholangitis, a rare, autoimmune cholestatic liver disease that puts patients at risk for life-threatening complications. Download your free research report on ICPT at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Donating blood is a life-saving act. Consider increasing your iron intake before and after you ...
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...View All